Evidence map›Paper›PMID 37886522›Full record

ArticleResearch square2023

Quantitative measurement of antibiotic resistance in

Joshua Carter, CRyPTIC Consortium

Abstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Joshua CarterStanford University.ORCID 0000-0002-9194-7966
CRyPTIC Consortium

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8M
Using the Mycobacterium tuberculosis Genome to Predict Tuberculosis Pathology, Drug Resistance Acquisition and Identify Community Transmission SitesR01AI146338 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GILMAN, ROBERT H · 2020 to 2024
$3.3M
Use of whole genome sequencing for tuberculosis diagnosticsR03AI117312 · NIAID · WADSWORTH CENTER · PI ESCUYER, VINCENT E., LAPIERRE, PASCAL · 2015 to 2016
$147k
NIAID NIH HHS R01 AI146338NIAID NIH HHS R03 AI117312NIGMS NIH HHS T32 GM007365OSELS CDC HHS U60 OE000103Wellcome Trust
6 · The paper itself

Abstract

The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis; however, molecular diagnostics to date have focused largely on first-line drugs and predicting binary susceptibilities. We used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration in 15,211

Identifiers

PMID37886522
PMCPMC10602118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.